Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
Overview | Financials
Company Name | Aurinia Pharmaceuticals Inc. |
Symbol | AUPH |
Currency | USD |
Price | 8.34 |
Market Cap | 1,192,544,940 |
Dividend Yield | 0% |
52-week-range | 4.71 - 10.05 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Peter S. Greenleaf M.B.A. |
Website | https://www.auriniapharma.com |
An error occurred while fetching data.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD